DDInter1607 DDInter1660
Ritonavir is an HIV protease inhibitor that interferes with the reproductive cycle of HIV. Although it was initially developed as an independent antiviral agent, it has been shown to possess advantageous properties in combination regimens with low-dose ritonavir and other protease inhibitors. It is now more commonly used as a booster of other protease inhibitors and is available in both liquid formulations and as capsules. While ritonavir is not an active antiviral agent against hepatitis C virus (HCV) infection, it is added in combination therapies indicated for the treatment of HCV infections as a booster. Ritonavir is a potent CYP3A inhibitor that increases peak and trough plasma drug concentrations of other protease inhibitors such as and overall drug exposure. American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) guidelines recommend ritonavir-boosted combination therapies as first-line therapy for HCV Genotype 1a/b and
Semaglutide is a glucagon-like peptide 1 (GLP-1) analog used to manage type 2 diabetes along with lifestyle changes, such as dietary restrictions and increased physical activity.[A31421,L8681] Other members of this drug class include [Exenatide] and [Liraglutide]. Semaglutide was developed by Novo Nordisk and approved by the FDA for subcutaneous injection in December 2017. The tablet formulation was approved for oral administration in September 2019. Semaglutide works by binding to and activating the GLP-1 receptor, thereby stimulating insulin secretion and reducing blood glucose. The subcutaneous injection is administered once weekly and the tablet is administered once a day. Semaglutide offers a competitive advantage over other drugs used to manage diabetes, which may require several daily doses. Clinical trials have determined that this drug reduces glycosylated hemoglobin (HbA1c) levels and reduces body weight, proving to be effective for patients with type 2 diabetes. In June 2021, semaglutide was approved by the FDA for chronic weight management in adults with general obesity or overweight who have at least one weight-related condition, marking semaglutide as the first approved drug for such use since 2014. The use of semaglutide in weight management is also approved by Health Canada and the EMA. On May 31, 2023, the FDA issued a warning regarding the use of compounded semaglutide after receiving adverse event reports. The use of salt forms of semaglutide, including semaglutide sodium and semaglutide acetate, has not been proven to be safe or effective.
Ritonavir {u} (Compound) resembles {v} (Compound) Atazanavir
Atazanavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Semaglutide
Ritonavir {u} (Compound) causes {v} (Side Effect) Dermatitis contact
Dermatitis contact {u} (Side Effect) is caused by {v} (Compound) Amcinonide
Amcinonide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Semaglutide
Ritonavir {u} (Compound) resembles {v} (Compound) Atazanavir
Atazanavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pasireotide
Pasireotide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Semaglutide
Ritonavir {u} (Compound) causes {v} (Side Effect) Dermatitis contact
Dermatitis contact {u} (Side Effect) is caused by {v} (Compound) Indinavir
Indinavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Semaglutide
Ritonavir {u} (Compound) resembles {v} (Compound) Atazanavir
Atazanavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Prednisolone
Prednisolone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Semaglutide
Ritonavir {u} (Compound) resembles {v} (Compound) Atazanavir
Atazanavir {u} may lead to a major life threatening interaction when taken with {v} Brigatinib
Brigatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Semaglutide
Ritonavir {u} (Compound) resembles {v} (Compound) Atazanavir
Atazanavir {u} (Compound) resembles {v} (Compound) Saquinavir
Saquinavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Semaglutide
Ritonavir {u} (Compound) resembles {v} (Compound) Atazanavir
Atazanavir {u} may lead to a major life threatening interaction when taken with {v} Methylprednisolone
Methylprednisolone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Semaglutide
Ritonavir {u} (Compound) causes {v} (Side Effect) Rash pustular
Rash pustular {u} (Side Effect) is caused by {v} (Compound) Gatifloxacin
Gatifloxacin {u} may lead to a major life threatening interaction when taken with {v} Semaglutide
Ritonavir {u} (Compound) resembles {v} (Compound) Atazanavir
Atazanavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bexarotene
Bexarotene {u} may lead to a major life threatening interaction when taken with {v} Semaglutide
Ritonavir (Compound) resembles Atazanavir (Compound) and Atazanavir may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Ritonavir (Compound) causes Dermatitis contact (Side Effect) and Dermatitis contact (Side Effect) is caused by Amcinonide (Compound) and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Semaglutide
Ritonavir (Compound) resembles Atazanavir (Compound) and Atazanavir may cause a moderate interaction that could exacerbate diseases when taken with Pasireotide and Pasireotide may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Ritonavir (Compound) causes Dermatitis contact (Side Effect) and Dermatitis contact (Side Effect) is caused by Indinavir (Compound) and Indinavir may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Ritonavir (Compound) resembles Atazanavir (Compound) and Atazanavir may cause a moderate interaction that could exacerbate diseases when taken with Prednisolone and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Ritonavir (Compound) resembles Atazanavir (Compound) and Atazanavir may lead to a major life threatening interaction when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Ritonavir (Compound) resembles Atazanavir (Compound) and Atazanavir (Compound) resembles Saquinavir (Compound) and Saquinavir may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Ritonavir (Compound) resembles Atazanavir (Compound) and Atazanavir may lead to a major life threatening interaction when taken with Methylprednisolone and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Ritonavir (Compound) causes Rash pustular (Side Effect) and Rash pustular (Side Effect) is caused by Gatifloxacin (Compound) and Gatifloxacin may lead to a major life threatening interaction when taken with Semaglutide
Ritonavir (Compound) resembles Atazanavir (Compound) and Atazanavir may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may lead to a major life threatening interaction when taken with Semaglutide